Clinical Trial Update: A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma [Phase 2]

View source ↗

Summary

A Phase 2 study comparing different doses of olodaterol delivered via the Respimat inhaler in patients with moderate to severe asthma has completed, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Striverdi Respimat (olodaterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2014-05-01